{
  "docId": "019de074-15c9-703f-ba69-83bd63385db9",
  "docSlug": "61dc585c6c50f6919636d426c025da60",
  "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 42 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 42,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "before_after",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 24,
  "notes": "The slide uses a split-panel design to compare two patient cohorts (ESR1m detectable vs not detectable).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-15c9-703f-ba69-83bd63385db9/25",
  "deckHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9",
  "deckJsonHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9.json",
  "deckAnchorHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.82
      },
      "kind": "callout",
      "text": "In the sub-population of patients with detectable ESR1m at baseline, camizestrant at both doses produces a clinically meaningful improvement in PFS over fulvestrant",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec4e329b-5612-401e-94f8-51c92a2d8982",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.45,
        "x": 0.52,
        "y": 0.23
      },
      "kind": "chart",
      "text": "Kaplan-Meier curve for ESR1m not detectable patients",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "61fe0285-5255-418d-b957-34653f23061f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.45,
        "x": 0.05,
        "y": 0.23
      },
      "kind": "chart",
      "text": "Kaplan-Meier curve for ESR1m detectable patients",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c23d4b15-e53c-475f-a9ee-2f541b72ce10",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "disclaimer",
      "text": "CI: confidence interval; CDK4/6i: CDK4/6 inhibitor; ESR1m: mutation in estrogen receptor 1 gene; HR: hazard ratio; PFS: progression-free survival. This presentation is the intellectual property of the author/presenter.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "426031cd-6bfa-4a0a-9a71-daa5244ceea8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.23,
        "x": 0.25,
        "y": 0.27
      },
      "kind": "table",
      "text": "Summary statistics for ESR1m detectable cohort",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "16f79dd4-6885-44e0-b8f6-ad45f9a19dea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.23,
        "x": 0.72,
        "y": 0.27
      },
      "kind": "table",
      "text": "Summary statistics for ESR1m not detectable cohort",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9ca8b856-48f0-40bb-82a5-8069fcb5a4b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.5,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "SERENA-2: PFS in patients by detectable ESR1m at baseline",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2e1d694f-320e-4144-9687-8622a2812642",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before-After-Bridge",
      "slug": "before-after-bridge",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "0936a037-fe62-4ef0-aa90-d256af2148c0",
      "evidence": "callout/primary: In the sub-population of patients with detectable ESR1m at baseline, camizestrant at both doses produces a clinically meaningful improvement in PFS over fulvestrant",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "before-after-framing",
      "slug": null,
      "matchId": "559bc587-2fa1-483c-a343-8cc9f9877d7b",
      "evidence": "The slide contrasts two patient populations (detectable vs not detectable) to highlight the efficacy of the drug in a specific sub-population.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 29,
      "from": 19,
      "beatId": "a90ff87c-6a94-47ae-8622-c8e4ab68f4ea",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "SERENA-2 trial data and conclusions",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 25,
      "from": 22,
      "name": "Before After",
      "slug": "21-before-after",
      "bestFor": "Product demos, process improvements, ROI justification",
      "matchId": "756e3074-1834-4f75-af20-e818e2b60802",
      "evidence": "SERENA-2 trial data",
      "position": 1,
      "objective": "How does SERENA-2 address patient needs?",
      "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta",
      "confidence": 0.7,
      "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}